NCT01248897已完成不适用
A Study of Biomarker Profiles in Asia Pacific erbB2+/HER2 Breast Cancer Patients Treated With Lapatinib and Other Anti-erbB2/HER2 Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 158
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
The purpose of this study is to understand how information of 3 specific biomarkers can provide guidance to physicians in the treatment of erbB2 positive breast cancer patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •HER2-positive (defined as either (a) IHC3+ or (b) FISH+ in local lab) recurrent / metastatic breast cancer patients who have received treatment with lapatinib-based regimen. These are either new, current or completed cases from any of the following settings:
- •treated according to physician's clinical judgement in routine practice; or
- •treated in clinical trials with known allocation to lapatinib-based regimen; or
- •treated via lapatinib expanded access or named patient programs. These regimens should contain lapatinib as the only anti-HER2 agent.
- •Exposed to < 2 lines of trastuzumab-based regimen in the metastatic setting prior to start of lapatinib-based regimen. These regimens should contain trastuzumab as the only anti-HER2 agent.
- •Patients with an historical tumor biopsy specimen available from their primary breast cancer diagnosis. If this is not available, then at least a specimen should be available anytime during the period before the patient started on any anti-HER2 therapy.
- •Willing to give written informed consent to release the tumor biopsy specimen with corresponding clinical data. If consent could be waived according to institutional practice (eg. patient already deceased, or patient previously provided blanket consent for institution to utilize tissue/data for research purpose), this is accepted with appropriate supporting documentation.
排除标准
- •Patients who have been exposed to other experimental anti-HER2 therapy eg. pertuzumab, trastuzumab-DM, neratinib, ertumaxomab, AV-412, BIBW2992, CUDC-101, anti-HER2 vaccines.
- •Other primary lesions that are not of breast origin.
结局指标
主要结局
Progression free survival
时间窗: Time from study entry to disease progression or death from any cause, in weeks
次要结局
- Response rate(Percentage of patients post-study entry showing complete or partial response to lapatinib)
- Progression free survival(Time from first initiation of any trastuzumab-based treatment to disease progression or death from any cause, in weeks)
- Overall survival(Time from study entry until death due to any cause, in weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic CancerChemotherapy EffectGenetic ChangePancreatic CancerNCT04110769Asan Medical Center10
进行中（未招募）
不适用
Biomarkers to Classify Heart FailureHeart FailureNCT02347722Ottawa Heart Institute Research Corporation511
已完成
不适用
Research of Biomarkers in Duchenne Muscular Dystrophy PatientsDuchenne Muscular Dystrophy (DMD)NCT01380964Genethon220
已完成
不适用
Brain Connectivity in Neurodevelopmental Disorders in Response to TreatmentFragile X SyndromeAutism Spectrum DisordersPsychosisNCT01364818University of North Carolina, Chapel Hill25
招募中
不适用
Biomarkers in Retinitis PigmentosaRetinitis PigmentosaNCT06306690Fondazione Policlinico Universitario Agostino Gemelli IRCCS35